Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDP in Urinary and Male Genital Tumors
NCT04718584Phase 2Completed
- Sponsor
- Dragonboat Biopharmaceutical
- Start
- Sep 2020
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lesabelimab in bladder cancer, renal cell carcinoma (RCC), penile carcinoma, sponsored by Dragonboat Biopharmaceutical. Started Sep 2020; status: completed.
02
Drugs
lesabelimab
03
Conditions
bladder cancerrenal cell carcinoma (RCC)penile carcinoma
Beyond the preview
Go deeper on NCT04718584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718584.